DTC Act of 2025
- Last Action
- 6/5/2025
Actions
- 2025-06-05Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-05Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-05Introduced in House
- 2025-06-05Introduced in House
CRS Summary
As of 2025-06-05 (00)
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Cosponsors (8)
- Janice Schakowsky (D-IL)
- Nicholas Begich (R-AK)
- Mike Quigley (D-IL)
- Robert Bresnahan (R-PA)
- Eleanor Norton (D-DC)
- Zachary Nunn (R-IA)
- Eugene Vindman (D-VA)
- Ashley Hinson (R-IA)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.